Estrogen receptor-negative breast ductal carcinoma: Clinicopathological features and Mib-1 (Ki-67) proliferative index association

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  MdPaiman, Noorasmaliza ^a,b   Md Ali, Siti Aishah ^a   MdZin, Reena ^a   Kamal, Meor Zamari Meor ^b   Md Amin, Wan Anna ^b   Nallusamy, Mohan ^b   Puspanathan, Pavitratha ^b   Muhammad, Rohaizak ^a   Wan Puteh, Sharifa Ezat ^a   Das, Srijit ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b HOSPITAL SULTANAH BAHIYAH   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN RECEPTOR NEGATIVE BREAST DUCTAL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84896504677     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089172     Document Type: Article

References (25)

1. Dodwell D, Williamson D (2008) Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer. Cancer Treat Rev 34: 137-144. (Pubitemid 351372884)
2. National Cancer Registry MoH (2003) Second report of National Cancer Registry Cancer incidence in Malaysia 2003. National Cancer Registry, Ministry of Health.
3. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, et al. (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295: 1658-1667.
4. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, et al. (2005) Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18: 26-35. (Pubitemid 40128091)
5. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, et al. (2004) Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10: 6622-6628. (Pubitemid 39346559)
6. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, et al. (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23: 7265-7277. (Pubitemid 46202341)
7. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17: 323-334.
8. Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, et al. (2001) Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebocontrolled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 10: 961-966. (Pubitemid 32844904)
9. Offersen BV, Sorensen FB, Knoop A, Overgaard J (2003) The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology 43: 573-582. (Pubitemid 38002346)
10. Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, et al. (2000) Prognostic value of histologic grade and proliferative activity in axillary nodepositive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 18: 2059-2069. (Pubitemid 30324359)
11. Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, et al. (2005) Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol 18: 1067-1078. (Pubitemid 41224497)
12. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science 235: 177-182. (Pubitemid 17231334)
13. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, et al. (1993) Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53: 4960-4970. (Pubitemid 23326194)
14. Hayes DF, Thor AD (2002) c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 29: 231-245. (Pubitemid 34620440)
15. Perts-Chuk LP (1996) Oestrogen receptor immunocytochemistry in parrafin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligandbinding assays. Cancer 77: 2514-2519.
16. Diaz LK, Sahin A, Sneige N (2004) Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. Ann Diagn Pathol 8: 23-27. (Pubitemid 38199175)
17. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481. (Pubitemid 29220854)
18. Rosa FE, Caldeira JR, Felipes J, Bertonha FB, Quevedo FC, et al. (2008) Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers. Hum Pathol 39: 720-730.
19. Jimenez RE, Wallis T, Visscher DW (2001) Centrally necrotizing carcinomas of the breast: a distinct histologic subtype with aggressive clinical behavior. Am J Surg Pathol 25: 331-337. (Pubitemid 32174202)
20. Gilchrist KW, Gray R, Fowble B, Tormey DC, Taylor SGt (1993) Tumor necrosis is a prognostic predictor for early recurrence and death in lymph nodepositive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol 11: 1929-1935. (Pubitemid 23304618)
21. Mersin H, Yildirim E, Berberoglu U, Gulben K (2008) The prognostic importance of triple negative breast carcinoma. Breast 17: 341-346.
22. Parl FF, Schmidt BP, Dupont WD, Wagner RK (1984) Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 54: 2237-2242. (Pubitemid 15210812)
23. Ben-Baruch A (2003) Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 5: 31-36. (Pubitemid 36553576)
24. Acs G, Esposito NN, Kiluk J, Loftus L, Laronga C (2012) A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in lowgrade invasive breast carcinomas. Mod Pathol 25: 556-566.
25. Drash A, Sherman F, Hartmann WH, Blizzard RM (1970) A syndrome of pseudohermaphroditism, Wilms' tumor, hypertension, and degenerative renal disease. Journal of Pediatrics 76: 585-593.